ClinicalTrials.gg
RecruitingNCT07175025NEXTUpdated Jun 18, 2026

The New Empowerment After eXposure to Trauma (NEXT) Study

An interventional study of Narrative Exposure Therapy (NET) in PTSD - Post Traumatic Stress Disorder and PTSD (Childbirth-Related), sponsored by Indiana University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Indiana University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

The NEXT Study is a randomized controlled pilot examining the feasibility and acceptability of a revised perinatal PTSD protocol. This study will randomize perinatal participants with PTSD to receive NET (n=45); treatment group) and will be compared to perinatal women randomized to usual care (n=45; comparator group). The overall objective of this project is to determine the most feasible and acceptable protocol for a brief virtual perinatal PTSD intervention.

02

Conditions studied

  • PTSD - Post Traumatic Stress Disorder
  • PTSD (Childbirth-Related)

Keywords

  • Pregnancy
  • Postpartum Period
  • Narrative Exposure Therapy
  • Post-Traumatic Stress Disorder
  • Brief interventions
03

In context

Combat Disorders

200 studies on the registry are indexed under Combat Disorders; 90 are open to participants now.

This study's planned enrollment of 106 is above the median of 72 across 167 interventional studies indexed under Combat Disorders.

Browse Combat Disorders studies →

Lead sponsor

Indiana University is the lead sponsor of 986 studies on the registry; 198 are open to participants now.

Of its 148 completed or terminated interventional studies of FDA-regulated products, 118 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • 18 years of age or older
  • able to read and speak English
  • diagnosis of probable PTSD as determined by the PTSD Checklist for (PCL-5)
  • pregnant or postpartum (delivered within 12 weeks) at the time of the eligibility screen Exclusion criteria
  • current severe suicide risk as determined by the Columbia Suicide Severity Rating Scale Screener (C-SSRS)
  • current psychotic or manic symptoms as determined by the DIAMOND screener and the Mood Disorder Questionnaire for Bipolar Disorder
  • cognitive impairment
  • concurrent trauma-focused psychotherapy
  • medical advice limiting participation in exposure therapy
  • current legal actions related to trauma
  • does not meet criteria for PTSD
  • not pregnant or delivered more than 12 weeks after timing of eligibility screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    Participants will complete a brief Narrative Exposure Therapy (NET) intervention. NET is a potent exposure-based intervention that is fully manualized, short-term, and developed for individuals with multiple traumas. NET is effective in as little as four sessions and can be completed virtually. NET involves four parts: 1) psychoeducation on trauma exposure and PTSD, 2) laying the Lifeline (constructing a life events inventory, including meaningful events and trauma exposures), 3) exposure sessions (retelling of a traumatic event while constructing the trauma narrative in the context of the life course), and 4) reading of the full written narrative, written by the study therapist after each exposure.

    Behavioral: Narrative Exposure Therapy (NET)

  • No intervention
    Usual Care Group

    This group will receive usual care for physical and mental health concerns during pregnancy and the postpartum period. Participation in the usual care group will consist of symptom monitoring (study staff) and participant's primary care/obstetric care for all other concerns. After enrollment in the study, the research assistant will have a structured 10-15 call/visit with usual care group participants to assess existing psychosocial support/health providers and provide a list of mental health services across IUSM and the state of Indiana/perinatal supports. They will encourage participants to follow-up with their primary care/obstetric care provider/community organizations for more help if needed. All usual care group participants will be offered the NET intervention after study assessments have been collected.

Interventions

  • BehavioralNarrative Exposure Therapy (NET)

    Narrative Exposure Therapy (NET) is the PTSD intervention for the treatment group.

06

What researchers measure

Primary outcomes

  1. Feasibility Tracking

    The investigators will determine feasibility by enrollment (≥75% of potential participants enroll), treatment adherence (≥80% of treatment group complete 5/6 NET sessions), assessment completion/each time point (≥75% of sample), and study completion (≥75% of sample).

    Time frame: Baseline, post-intervention time period (12 weeks post-baseline), and follow-up (24 weeks post-baseline)

  2. Acceptability

    The Triple P-Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), \& Feasibility of Intervention Measure (FIM) scales will be used to assess overall acceptability of the NEXT protocol

    Time frame: Post-intervention time period (12 weeks post-baseline)

  3. Perinatal NET Protocol Acceptability Questionnaire (PNPAQ)

    A 20-item study-specific measure used to assess various PNET protocol components as well as 10 exploratory questions on acceptability of potential future protocol elements (e.g., collection biomarkers, in person v. virtual).

    Time frame: Post-intervention time period (12 weeks post-baseline) for the NET treatment group

Secondary outcomes

  1. PTSD Checklist for DSM-5 (PCL-5)

    Self-report assessment of PTSD symptoms in response to a traumatic event in past week or past month

    Time frame: *Baseline, post-intervention time period (12 weeks post-baseline), and follow-up (24 weeks post-baseline). *Weekly to biweekly administration across 12 week intervention period

  2. Edinburgh Postnatal Depression Scale (EPDS)

    Self-report assessment of depressive symptoms in the perinatal period, including suicidality.

    Time frame: *Baseline, post-intervention time period (12 weeks post-baseline), and follow-up (24 weeks post-baseline). *Weekly to biweekly administration across 12 week intervention period

  3. Life Events Checklist (LEC)

    Used to self-report traumatic events over the lifetime at start of study as well as any new traumas experienced during treatment period.

    Time frame: Baseline, post-intervention time period (12 weeks post-baseline), and follow-up (24 weeks post-baseline)

  4. Perinatal Quality of Life

    Mother-Generated Index (MGI) will be used to assess valued life domains by specifying up to eight areas of their lives which have been affected by being pregnant/ giving birth to a baby, assessing how the participant felt about this area over the previous month, and describing the domains most important to her.

    Time frame: Baseline, post-intervention time period (12 weeks post-baseline), and follow-up (24 weeks post-baseline)

Other outcomes

  1. Parental Stress Scale (PSS)

    Exploratory self-report measure that assesses participants' feelings about their parenting role

    Time frame: Baseline, post-intervention time period (12 weeks post-baseline), and follow-up (24 weeks post-baseline)

  2. Treatment Tracking

    A brief study-specific measure to assess changes to medication doses and/or psychotherapy

    Time frame: *Baseline, post-intervention time period (12 weeks post-baseline), and follow-up (24 weeks post-baseline) *Weekly to biweekly across 12 week intervention time period

  3. Perinatal Life Events Checklist

    Exploratory study specific self-report measure used to assess potentially traumatic events that occur during pregnancy and the postpartum period.

    Time frame: Baseline and follow-up (24 weeks post-baseline)

  4. Posttraumatic Growth Inventory (PGI)

    A self-report measure assessing to assess post-trauma growth and self-improvement a person undergoes.

    Time frame: Baseline, post-intervention time period (12 weeks post-baseline), and follow-up (24 weeks post-baseline)

  5. Centrality of Event (CE)

    This 7-item measure assesses how central a traumatic event is to a participant's identity and life story and if that changes with intervention.

    Time frame: Baseline, post-intervention time period (12 weeks post-baseline), and follow-up (24 weeks post-baseline)

  6. Social Isolation

    The UCLA 3-item Social Isolation scale will be used to assess loneliness and social isolation, a predictor of maternal health.

    Time frame: Baseline, post-intervention time period (12 weeks post-baseline), and follow-up (24 weeks post-baseline)

  7. Therapist Alliance

    The Working Alliance Inventory-Short-Form (WAI-SF) will be used to assess how participant feels about fit with study therapist assigned to them at mid- and end of treatment.

    Time frame: *Week 4 of intervention period *Post-intervention time period (12 weeks post-baseline) for the NET treatment group

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Miller ML, Wasson RS, Jiang LJ, Ward MJ, Meyer DJ, Haas DM. Narrative Exposure Therapy: Expanding Virtual Treatment of Posttraumatic Stress Disorder to the Postpartum Period. J Aggress Maltreat Trauma. 2025;34(4):538-557. doi: 10.1080/10926771.2025.2491772. Epub 2025 Apr 20. PubMed 40395722 ↗
  • Stevens NR, Miller ML, Soibatian C, Otwell C, Rufa AK, Meyer DJ, Shalowitz MU. Exposure therapy for PTSD during pregnancy: a feasibility, acceptability, and case series study of Narrative Exposure Therapy (NET). BMC Psychol. 2020 Dec 9;8(1):130. doi: 10.1186/s40359-020-00503-4. PubMed 33298159 ↗

Individual participant data

Plan to share: Yes — We will share the study protocol, Statistical Analysis Plan (SAP), and Informed Consent Form (ICF)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The Study Protocol and SAP will be pre-registered and available at the start of the trial (9/15/25). The Informed Consent form will be approved by the Institution IRB prior to the start of the trial and available by request. There is not a specified end date for these materials.

Access criteria: The study team currently has access to all documents and the Study Protocol and SAP are available through the OSF preregistration website.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07175025
Lead sponsor
Indiana University
Responsible party
Michelle L. Miller (Assistant Professor, Indiana University) — Principal investigator
First posted
Sep 16, 2025
Start date
Sep 24, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Jun 18, 2026

Study contacts

Michelle L. Miller, PhD
Contact
mlm41@iu.edu
317-963-7257
Neva Brown, BA
Contact
mlm41@iu.edu
Michelle L. Miller, PhD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion